Loading…
French clinical-stage biotech developing obefazimod, an oral drug for ulcerative colitis and other inflammatory diseases.
French clinical-stage biotech developing obefazimod, an oral drug for ulcerative colitis and other inflammatory diseases.
Has no product revenue. Trials are paid for by share sales and loans, and the company is built around one oral drug, obefazimod, which raises levels of a molecule called miR-124 that calms inflammation.
Moat: none (IP / patents). Pre-revenue clinical-stage biotech; value depends entirely on obefazimod's trial and regulatory success.
Headquarters: Paris, France · Founded: 2013 · Employees: 69
Size Abivax (ABVX.PA) is a France Health Care company (Pharmaceuticals: Other) with a market value of $7.58B, the 53rd largest of 206 France companies the cockpit tracks. Shares closed at €77.15 on 6 Nov 2026.
Performance Over six months the shares fell 25.5%, against -2.0% for the median peer and -0.4% for the France market (cap-weighted) — lowest of 17 in its peer set.
Next results Next results expected around 14 Dec 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | €0 | €0 | €0 | €0 | €0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -€1.29M | -€1.07M | -€1.10M | -€707,000 | -€485,000 |
| EBITDA | -€296M | -€250M | -€184M | -€131M | -€55.3M |
| Net income | -€401M | -€336M | -€176M | -€148M | -€60.7M |
| Free cash flow | -€194M | -€162M | -€154M | -€100M | -€58.2M |
| Capital expenditure | €245,000 | €142,000 | €643,000 | €266,000 | €323,000 |
| Total debt | €1.21M | €32.1M | €96.2M | €55.5M | €39.2M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Abivax ABVX.PA | $7.58B | -25% | n/a | n/a | n/a | n/a |
| AbbVie ABBV | $515B | +45% | +11% | 36% | 8.9× | -0.1% |
| Pfizer PFE | $168B | +14% | +1% | 26% | 3.4× | -4.3% |
| Bristol Myers Squibb BMY | $127B | +12% | +4% | 33% | 3.2× | -12.9% |
| Roche RO.SW | $385B | +22% | -1% | 31% | 5.6× | 0.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ABVX.PA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +0.1% | +3.7% | 6th lowest of 17 |
| 6-month return | -25.5% | -2.0% | lowest of 17 |
| Distance from 52-week high | -44.5% | -19.5% | lowest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Abivax ABVX.PA | France | $7.58B | -25% | n/a | n/a | n/a | n/a | n/a |
| Lupin LUPIN.NS | India | $9.65B | -19% | +24% | 24% | 2.9× | 8.8% | +13.0% |
| Aurobindo Pharma AUROPHARMA.NS | India | $10.9B | +22% | +14% | 15% | 2.8× | 21.0% | +6.3% |
| Dong-E-E-Jiao 000423.SZ | China | $4.80B | -8% | +8% | 29% | 3.6× | -4.6% | +14.5% |
| Cipla CIPLA.NS | India | $12.1B | +4% | -1% | 13% | 3.8× | 28.2% | +8.1% |
| Zhejiang NHU 002001.SZ | China | $12.3B | -23% | +11% | 33% | 3.1× | -7.8% | +16.7% |
| Shijiazhuang Yiling Pharmaceutical 002603.SZ | China | $4.02B | -6% | +32% | 21% | 3.1× | -3.2% | -2.2% |
| Guangdong Zhongsheng Pharmaceutical 002317.SZ | China | $3.13B | +35% | -14% | 9% | 9.3× | 34.7% | +5.9% |
| Bausch Health Companies BHC.TO | Canada | $3.09B | +48% | +10% | 27% | 2.0× | -14.5% | +5.9% |
| Jilin Aodong Pharmaceutical 000623.SZ | China | $3.02B | -9% | -4% | -13% | 8.6× | 5.2% | +1.0% |
| By-health 300146.SZ | China | $2.61B | -1% | +10% | 11% | 2.0× | 5.1% | +0.6% |
| China Resources Double-Crane Pharmaceutical 600062.SS | China | $2.50B | -10% | -1% | 13% | 1.6× | -8.3% | +5.3% |
| China Resources Jiangzhong Pharmaceutical 600750.SS | China | $2.19B | -3% | -10% | 24% | 3.9× | -2.5% | +11.6% |
| Granules India GRANULES.NS | India | $2.10B | +8% | +22% | 17% | 3.3× | 23.5% | +10.6% |
| Health and Happiness (H&H) International 1112.HK | Hong Kong | $2.05B | +70% | +24% | 16% | 1.3× | -3.0% | +4.4% |
| China Meheco 600056.SS | China | $2.00B | -14% | +2% | 3% | 0.6× | -0.8% | -2.1% |
| Porton Pharma Solutions 300363.SZ | China | $1.92B | +14% | +6% | -2% | 3.6× | 5.3% | +10.4% |